BRIEF-Lilly's Jaypirca (Pirtobrutinib) Recommended By CHMP For Approval In The European Union For Adults With Chronic Lymphocytic Leukemia (Cll) Across All Lines Of Therapy

Eli Lilly and Company

LLY

0.00

June 26 (Reuters) - Eli Lilly and Co LLY.N:

LILLY'S JAYPIRCA (PIRTOBRUTINIB) RECOMMENDED BY CHMP FOR APPROVAL IN THE EUROPEAN UNION FOR ADULTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) ACROSS ALL LINES OF THERAPY
ELI LILLY - SUBMITS JAYPIRCA FOR FDA APPROVAL IN CLL; DECISION EXPECTED SECOND HALF 2026
ELI LILLY - APPLICATION FOR JAYPIRCA REFERRED TO EUROPEAN COMMISSION; DECISION EXPECTED IN ONE TO TWO MONTHS

Source text: ID:nPnSQ5JSa

Further company coverage: LLY.N

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.